10 August 2015 - Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Vitaros, a topical cream indicated for the treatment of patients with erectile dysfunction ("ED"), has been approved through the European Decentralized Procedure ("DCP") in twelve additional countries. Those countries are: Austria, Cyprus, the Czech Republic, Denmark, Finland, Greece, Iceland, Norway, Poland, Portugal, Romania and the Slovak Republic. Apricus' commercialization partners that hold the license for these additional territories will be responsible for the next step of obtaining national phase approvals in order to make Vitaros ready to launch.

In 2013, Vitaros was approved under a separate DCP in Belgium, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Spain, Sweden and the United Kingdom. Under the DCP, Apricus or its partners filed applications for marketing approval designating the Netherlands as the Reference Member State on behalf the twenty-one other European Concerned Member States participating in the procedure.

For more details, go to: http://ir.apricusbio.com/phoenix.zhtml?c=118007&p=irol-newsArticle&ID=2078275